Clinical Trial Update: Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma [Phase 1]

View source ↗

Summary

Phase 1 trial of ST-001 nanoFenretinide for relapsed/refractory T-cell non-Hodgkin lymphoma is currently recruiting, targeting multiple T-cell lymphoma subtypes…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Angioimmunoblastic T-cell Lymphoma
• Cutaneous T-cell Lymphoma
• Follicular T-cell Lymphoma
• Mycosis Fungoides
• Peripheral T-cell Lymphoma
• Sézary Syndrome
• T-cell Lymphoma

Drugs mentioned

• ST-001 nanoFenretinide (fenretinide)

Snippet

Sponsor: SciTech Development, Inc. | Conditions: T-cell Lymphoma, Cutaneous/Peripheral T-Cell Lymphoma | Phase 1 | Status: RECRUITING